Foresite Capital Management VI LLC
An institutional investment manager in WEST HOLLYWOOD, CA. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 2013341.
- Reported value$642.6m
- Positions23
Holdings: 23 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| CG Oncology, Inc.CGON | COM | 156944100 | 168 | 26.2% | 2,369,574 | Added+148,100 | |
| Alumis Inc.ALMS | COM | 022307102 | 120 | 18.6% | 4,247,670 | Unchanged | |
| Seaport Therapeutics, Inc.SPTX | COM | 81221K108 | 38.7 | 6.0% | 1,779,521 | New+1,779,521 | |
| Denali Therapeutics Inc.DNLI | COM | 24823R105 | 35.9 | 5.6% | 1,396,771 | Added+186,800 | |
| Celldex Therapeutics, Inc.CLDX | COM | 15117B202 | 32.7 | 5.1% | 879,713 | Added+563,800 | |
| Agios Pharmaceuticals, Inc.AGIO | COM | 00847X104 | 29.1 | 4.5% | 785,000 | Added+260,000 | |
| Corvus Pharmaceuticals, Inc.CRVS | COM | 221015100 | 27.4 | 4.3% | 1,831,233 | Unchanged | |
| Parabilis Medicines, Inc.PBLS | COM | 698955101 | 27.3 | 4.3% | 999,044 | New+999,044 | |
| GH Research PLC | ORD | G3855L106 | 25.3 | 3.9% | 940,493 | Added+625,001 | |
| Jade Biosciences, Inc.JBIO | COM | 008064206 | 19.7 | 3.1% | 886,667 | Added+566,667 | |
| Hinge Health, Inc.HNGE | CL A | 433313103 | 18.3 | 2.8% | 220,400 | Unchanged | |
| Kymera Therapeutics, Inc.KYMR | COM | 501575104 | 16.8 | 2.6% | 146,332 | Unchanged | |
| AtaiBeckley Inc. | COM | 04650F101 | 14.5 | 2.3% | 2,750,000 | Unchanged | |
| Verastem, Inc.VSTM | COM | 92337C203 | 12.0 | 1.9% | 3,146,631 | Unchanged | |
| Beam Therapeutics Inc.BEAM | COM | 07373V105 | 11.3 | 1.8% | 330,000 | New+330,000 | |
| Minerva Neurosciences, Inc.NERV | COM | 603380205 | 11.0 | 1.7% | 1,985,584 | Reduced−1,016 | |
| ArriVent BioPharma, Inc.AVBP | COM | 04272N102 | 10.5 | 1.6% | 301,341 | New+301,341 | |
| Aura Biosciences, Inc.AURA | COM | 05153U107 | 9.5 | 1.5% | 1,333,334 | New+1,333,334 | |
| Crinetics Pharmaceuticals, Inc. | COM | 22663K107 | 7.9 | 1.2% | 212,010 | Unchanged | |
| Research Alliance Corp III | CL A | G75226103 | 3.2 | 0.5% | 300,000 | New+300,000 | |
| Zura Bio Ltd | CL A | G9TY5A101 | 2.7 | 0.4% | 450,000 | Unchanged | |
| Kailera Therapeutics, Inc.KLRA | COM | 482931102 | 0.8 | 0.1% | 37,500 | New+37,500 | |
| Disc Medicine, Inc.IRON | COM | 254604101 | 0.1 | <0.1% | 970 | New+970 |
Sold out: 2 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−1,364,019 | |
| OnKure Therapeutics, Inc.OKUR | COM CL A | 68277Q105 | 0.0 | 0.0% | 0 | Sold out−1,445,783 |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-097133 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.